MCID: TRC003
MIFTS: 44

Trichomoniasis

Categories: Infectious diseases, Nephrological diseases, Reproductive diseases

Aliases & Classifications for Trichomoniasis

MalaCards integrated aliases for Trichomoniasis:

Name: Trichomoniasis 12 77 56 44 15 3
Trichomonas Infections 45 74
Trichomonas Infection 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1947
ICD9CM 36 131 131.9
MeSH 45 D014245
NCIt 51 C35720
SNOMED-CT 69 56335008
ICD10 34 A59 A59.9
UMLS 74 C0040921

Summaries for Trichomoniasis

MedlinePlus : 44 Trichomoniasis is a sexually transmitted disease caused by a parasite. It spreads from person to person during sex. Many people do not have any symptoms. If you do get symptoms, they usually happen within 5 to 28 days after being infected. It can cause vaginitis in women. Symptoms include Yellow-green or gray discharge from the vagina Discomfort during sex Vaginal odor Painful urination Itching burning, and soreness of the vagina and vulva Most men do not have symptoms. If they do, they may have Itching or irritation inside the penis Burning after urination or ejaculation Discharge from the penis Trichomoniasis can increase the risk of getting or spreading other sexually transmitted diseases. Pregnant women with trichomoniasis are more likely to give birth too early, and their babies are more likely have a low birth weight. Lab tests can tell if you have the infection. Treatment is with antibiotics. If you are infected, you and your partner must be treated. Correct usage of latex condoms greatly reduces, but does not eliminate, the risk of catching or spreading trichomoniasis. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. Centers for Disease Control and Prevention

MalaCards based summary : Trichomoniasis, also known as trichomonas infections, is related to vaginitis and bacterial vaginosis, and has symptoms including fever, pruritus and pelvic pain. An important gene associated with Trichomoniasis is IL2 (Interleukin 2), and among its related pathways/superpathways are Calcineurin-regulated NFAT-dependent transcription in lymphocytes and Immune response IFN alpha/beta signaling pathway. The drugs Acetylcysteine and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include testes, spinal cord and cervix.

Disease Ontology : 12 A parasitic protozoa infectious disease that is caused by singled-celled protozoan parasites Trichomonas vaginalis or Trichomonas tenax, which infect the urogenital tract and mouth respectively.

CDC : 3 Trichomoniasis is common and easy to cure.

Wikipedia : 77 Trichomoniasis (trich) is an infectious disease caused by the parasite Trichomonas vaginalis. About 70%... more...

Related Diseases for Trichomoniasis

Diseases related to Trichomoniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Related Disease Score Top Affiliating Genes
1 vaginitis 33.0 CXCL8 LAP3
2 bacterial vaginosis 31.1 CXCL8 LAP3
3 urethritis 30.6 EXTL3 YME1L1
4 trypanosomiasis 29.6 CXCL8 IL2
5 trichomonas vaginalis trichomoniasis 12.4
6 trichomonas tenax trichomoniasis 12.4
7 dientamoebiasis 11.6
8 candidiasis 10.6
9 chlamydia 10.3
10 infertility 10.3
11 vaginal discharge 10.3
12 toxicodendron dermatitis 10.2 CXCL8 IL2
13 campylobacteriosis 10.2
14 streptococcal toxic-shock syndrome 10.2 CXCL8 IL2
15 clonorchiasis 10.2 CXCL8 IL2
16 retinitis pigmentosa 44 10.2 CXCL8 IL2
17 crohn's colitis 10.2 CXCL8 IL2
18 capillary leak syndrome 10.2 CXCL8 IL2
19 asymptomatic neurosyphilis 10.2 CXCL8 EXTL3
20 necrotizing fasciitis 10.2 CXCL8 IL2
21 vulvovaginal candidiasis 10.2
22 wells syndrome 10.2 CXCL8 IL2
23 prostatitis 10.2 CXCL8 IL2
24 pleurisy 10.2 CXCL8 IL2
25 brucellosis 10.2 CXCL8 IL2
26 tonsillitis 10.1 CXCL8 IL2
27 cervical cancer 10.1
28 giardiasis 10.1
29 syphilis 10.1
30 human immunodeficiency virus infectious disease 10.1
31 herpes simplex 10.1
32 keratoconjunctivitis 10.1 CXCL8 IL2
33 conjunctivitis 10.1 CXCL8 IL2
34 visceral leishmaniasis 10.1 CXCL8 IL2
35 urethral syndrome 10.1 EXTL3 WASF3
36 primary bacterial infectious disease 10.0 CXCL8 EXTL3 IL2
37 retinitis pigmentosa 10.0
38 vulvovaginitis 10.0
39 amebiasis 10.0
40 vaginal disease 10.0 CXCL8 EXTL3 LAP3
41 bone inflammation disease 10.0 CXCL8 IL2
42 cervicitis 10.0 CXCL8 IL2 YME1L1
43 toxic shock syndrome 10.0 CXCL8 IL2
44 cystic fibrosis 9.9
45 human immunodeficiency virus type 1 9.9
46 pelvic inflammatory disease 9.9
47 filariasis 9.9
48 anogenital venereal wart 9.9
49 diarrhea 9.9
50 urinary schistosomiasis 9.9

Comorbidity relations with Trichomoniasis via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential

Graphical network of the top 20 diseases related to Trichomoniasis:



Diseases related to Trichomoniasis

Symptoms & Phenotypes for Trichomoniasis

UMLS symptoms related to Trichomoniasis:


fever, pruritus, pelvic pain

Drugs & Therapeutics for Trichomoniasis

Drugs for Trichomoniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Metronidazole Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 443-48-1 4173
3
Clindamycin Approved, Vet_approved Phase 4,Early Phase 1 18323-44-9 29029
4
Clotrimazole Approved, Vet_approved Phase 4,Phase 3 23593-75-1 2812
5
Tinidazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19387-91-8 5479
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7 Antioxidants Phase 4
8 Expectorants Phase 4
9 N-monoacetylcystine Phase 4
10 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
11 Antidotes Phase 4
12 Antiviral Agents Phase 4,Phase 2,Phase 1,Not Applicable
13 Free Radical Scavengers Phase 4
14 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
15 cysteine Phase 4
16 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
17 Antibiotics, Antitubercular Phase 4
18 Respiratory System Agents Phase 4
19 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
20 Protective Agents Phase 4,Phase 3
21 Contraceptive Agents Phase 4,Phase 3,Not Applicable
22 Clindamycin palmitate Phase 4,Early Phase 1
23 Clindamycin phosphate Phase 4,Early Phase 1
24
Ethanol Approved Phase 2, Phase 3,Phase 3,Not Applicable 64-17-5 702
25
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Early Phase 1 22916-47-8 4189
26
Fluconazole Approved, Investigational Phase 3,Early Phase 1 86386-73-4 3365
27
Secnidazole Approved Phase 3 3366-95-8
28
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
29
Polymyxin B Approved, Vet_approved Phase 3 1404-26-8
30
Neomycin Approved, Vet_approved Phase 3 1404-04-2 8378
31
Azithromycin Approved Phase 3,Phase 2 83905-01-5 55185 447043
32
leucovorin Approved Phase 3 58-05-9 6006 143
33
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
34
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
35
Iron Approved, Experimental Phase 3 7439-89-6, 15438-31-0 23925 27284
36
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
37
Histamine Approved, Investigational Phase 3 51-45-6 774
38
Cetirizine Approved Phase 3 83881-51-0 2678
39
Acetaminophen Approved Phase 3 103-90-2 1983
40
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
41
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
42
ofatumumab Approved Phase 3 679818-59-8 6918251
43
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
44
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
45
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
47
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
48
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
49
Dihydroartemisinin Experimental, Investigational Phase 3 71939-50-9 6918483
50
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
2 Trichomonas Vaginalis Recurrence Among HIV+ Women Completed NCT01018095 Phase 4 Metronidazole
3 Stage Matched Intervention to Increase Dual Method Use Completed NCT00436306 Phase 4
4 Comparison of Two Topical Formulations Containing Clindamycin and Clotrimazole in Patients With Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
5 Evaluation of Efficacy and Safety of Gynomax® XL Ovule Not yet recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
6 Trichomonas Vaginalis Repeat Infections Among HIV Negative Women Completed NCT01832480 Phase 3 MTZ 500 mg twice daily x 7 days;MTZ 2 g
7 Intravaginal Treatment of Disturbances of Vaginal Flora Among HIV Infected and Uninfected Women in Malawi Completed NCT00140764 Phase 3 Metronidazole gel versus placebo gel
8 Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission Completed NCT00213083 Phase 3 Carraguard (PC-515)
9 Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic Completed NCT00947271 Phase 3
10 Effect of HIV/STD Risk Reduction Program on South African Adolescents Completed NCT00559403 Phase 2, Phase 3
11 Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge Completed NCT02111629 Phase 3 Fluconazole and Secnidazole
12 Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk Populations Completed NCT00710060 Phase 3
13 Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis Completed NCT02515656 Phase 3 POLYGYNAX®;GYNODAKTARIN®;Placebo
14 A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom Completed NCT01223313 Phase 3
15 Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
16 MEMA Kwa Vijana Trial: Impact of an Adolescent Sexual and Reproductive Health Intervention in Mwanza, Tanzania Completed NCT00248469 Phase 3
17 Gestational Sulfadoxine-pyrimethamine and Azithromycin Treatment to Prevent Preterm Birth Completed NCT00131235 Phase 3 Sulfadoxine-pyrimethamine treatment twice during pregnancy;Sulfadoxine-pyrimethamine at 4-week intervals;Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice
18 Supplementing Maternal and Infant Diet With High-energy, Micronutrient Fortified Lipid-based Nutrient Supplements (LNS) Completed NCT01239693 Phase 3
19 Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa Not yet recruiting NCT03208179 Phase 3 dihydroartemisinin-piperaquine;sulphadoxine-pyrimethamine;dihydroartemisinin-piperaquine plus azithromycin
20 Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa Terminated NCT01103063 Phase 3 Azithromycin plus chloroquine;sulfadoxine-pyrimethamine
21 Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris Terminated NCT02613910 Phase 3 Ofatumumab;Acetaminophen/paracetamol;Antihistamine (cetirizine or equivalent);Prednisone/Prednisolone
22 Effectiveness of the Diaphragm for HIV Prevention Withdrawn NCT00121459 Phase 3
23 Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis Completed NCT01361048 Phase 2 oral metronidazole;neo penotran forte;neo penotran forte once a day
24 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women Completed NCT01230814 Phase 2 Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate);Placebo
25 Study to Improve Partner Services for STD Prevention Completed NCT00207467 Phase 2
26 HIV/STI Risk Reduction for Incarcerated Women With Interpersonal Violence Completed NCT01907126 Phase 2
27 Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission Completed NCT00213018 Phase 2 Carraguard (PC-515)
28 Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide Completed NCT00213031 Phase 2 Carraguard (PC-515)
29 The Multimedia HIV/STI Prevention for Drug-Involved Female Offenders Completed NCT01784809 Phase 2
30 Behavioral Intervention to Reduce Sexual and Injection Risks Among Female Sex Workers Who Also Inject Drugs in Mexico Completed NCT00840658 Phase 2
31 Safer Sex Program for Young African-American Men Completed NCT01439503 Phase 2
32 A Web-based Intervention Study to Reduce High-risk Sexual Behavior by Persons Living With HIV AIDS (PLWH) Completed NCT01198418 Phase 1, Phase 2
33 NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole) Completed NCT00322465 Phase 2 Tinidazole;Doxycycline;Azithromycin
34 BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women Completed NCT00074425 Phase 2 BufferGel;PRO 2000/5 Gel;Placebo gel
35 Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB Active, not recruiting NCT02748356 Phase 2 Lactobacillus
36 Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB Active, not recruiting NCT02748317 Phase 2 Lactobacillus rhamnosus GG
37 Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa Withdrawn NCT02462772 Phase 2 cabotegravir;Placebo
38 Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions Completed NCT01591889 Phase 1 Tinidazole;Tinidazole
39 Safety and Acceptability of Carraguard™ Among HIV-negative Couples in Thailand Completed NCT00213057 Phase 1 Carraguard (PC-515)
40 S.T.A.R.S.: Sistas Talking About Real Solutions Completed NCT01028157 Phase 1
41 Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Vaginal Ring Completed NCT02920827 Phase 1
42 A Safety Study to Assess the Delivery of Dapivirine From a Matrix Vaginal Ring Completed NCT01144676 Phase 1 dapivirine;placebo;dapivirine;placebo
43 A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium Withdrawn NCT01242579 Phase 1 Maraviroc/Dapivirine Gel;Dapivirine Vaginal Gel;Maraviroc Vaginal Gel;Matching Placebo Gel
44 Accuracy and Acceptability of Self-Diagnostic Methods for Vaginitis in Adolescent Females Unknown status NCT00706368 Not Applicable
45 The Impact of Short-term Financial Incentives on Sexual Behavior and HIV Incidence in Lesotho Unknown status NCT01589965 Early Phase 1
46 The Contraceptive Choice Project Unknown status NCT01986439
47 Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method Unknown status NCT02558179
48 Increased Access to Emergency Contraceptive Pills Unknown status NCT00060463 Not Applicable
49 "Solana™ Trichomonas Assay Field Study" Completed NCT02566447
50 Control of Trichomoniasis Completed NCT00334555 Not Applicable

Search NIH Clinical Center for Trichomoniasis

Cochrane evidence based reviews: trichomonas infections

Genetic Tests for Trichomoniasis

Anatomical Context for Trichomoniasis

MalaCards organs/tissues related to Trichomoniasis:

42
Testes, Spinal Cord, Cervix, T Cells, Skin, Colon

Publications for Trichomoniasis

Articles related to Trichomoniasis:

(show top 50) (show all 675)
# Title Authors Year
1
Treatment recommendations for trichomoniasis in women. ( 30587286 )
2019
2
Chemotherapeutic options for the treatment of human trichomoniasis. ( 30612993 )
2019
3
Trichomonas vaginalis virus (TVV) among women with trichomoniasis and associations with demographics, clinical outcomes, and metronidazole resistance. ( 30768180 )
2019
4
The dawn of novel STI prevention methods: modelling potential unintended effects of changes in cervical cancer screening guidelines on trichomoniasis. ( 29545472 )
2018
5
Humoral and T cell-mediated immune response against trichomoniasis. ( 29266263 )
2018
6
Controlled delivery of the antiprotozoal agent (tinidazole) from intravaginal polymer matrices for treatment of the sexually transmitted infection, trichomoniasis. ( 29799300 )
2018
7
Chlorinated metronidazole as a promising alternative for treating trichomoniasis. ( 29502297 )
2018
8
The Prevalence of Trichomoniasis in Women Referred to Clinical Centers in South of Tehran, Iran during 2015-2016. ( 29963092 )
2018
9
Longitudinal trajectory of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis during pregnancy as well as the impact on pregnancy outcomes: a preliminary study. ( 29685081 )
2018
10
Incidence of Antenatal Trichomoniasis and Evaluation of Its Role as a Cause of Preterm Birth in Pregnant Women Referring to Minia University Hospital, Egypt. ( 29963086 )
2018
11
A retrospective epidemiological analysis of shared risk factors for bovine trichomoniasis and bovine genital campylobacteriosis in La Pampa province (Argentina). ( 30466651 )
2018
12
Survey of Obstetrician-Gynecologists in the United States about Trichomoniasis, 2016. ( 29994936 )
2018
13
Metronidazole-Resistant Trichomoniasis: Beneficial Pharmacodynamic Relationship with High-dose Oral Tinidazole and Vaginal Paromomycin Combination Therapy. ( 30106840 )
2018
14
Aptima Trichomonas vaginalis assay elucidates significant underdiagnosis of trichomoniasis among women in Brazil according to an observational study. ( 30154157 )
2018
15
The need for new treatment recommendations for trichomoniasis among women. ( 30297321 )
2018
16
Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. ( 30297322 )
2018
17
Incidence and predictors of reinfection with trichomoniasis based on nucleic acid amplification testing results in HIV-infected patients. ( 30486764 )
2018
18
New treatment recommendations for trichomoniasis in women. ( 30507449 )
2018
19
Is It Time to Stop Using Single Dose Oral Metronidazole for the Treatment of Trichomoniasis in Women? ( 30657463 )
2018
20
Prevalence and genotyping of Trichomonas infections in wild birds in central Germany. ( 30092001 )
2018
21
Single-Dose Compared With Multidose Metronidazole for the Treatment of Trichomoniasis in Women: A Meta-Analysis. ( 27898571 )
2017
22
Antitrichomonal activity of Peganum harmala alkaloid extract against trichomoniasis in Pigeon (Columba livia domestica). ( 28084792 )
2017
23
Report of the first clinical case of intestinal trichomoniasis caused by Tritrichomonas foetus in a cat with chronic diarrhoea in Brazil. ( 28412947 )
2017
24
Diagnosis of Trichomoniasis in Male Patients on Performing Nested Polymerase Chain Reaction. ( 29035239 )
2017
25
Is there an association between trichomoniasis and other sexually transmitted infections in adolescent ED patients? ( 29229536 )
2017
26
An evaluation study of the Becton-Dickinson ProbeTec Qx (BDQx) Trichomonas vaginalis trichomoniasis molecular diagnostic test in two large, urban STD services. ( 28108699 )
2017
27
The prevalence of trichomoniasis and associated factors among women treated at a university hospital in southern Brazil. ( 28346531 )
2017
28
A Study on the Prevalence of Genital Trichomoniasis among Female Outpatients Attending Sexually Transmitted Infection Clinic in a Tertiary Care Hospital. ( 28042211 )
2017
29
Intravaginal boric acid: is it an alternative therapeutic option for vaginal trichomoniasis? ( 29223972 )
2017
30
Very low sensitivity of wet mount microscopy compared to PCR against culture in the diagnosis of vaginal trichomoniasis in Uganda: a cross sectional study. ( 28683790 )
2017
31
Natural Products as New Treatment Options for Trichomoniasis: A Molecular Docking Investigation. ( 28134827 )
2017
32
A missed diagnosis of trichomoniasis. ( 28085787 )
2017
33
Recombinant I+-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis. ( 28209207 )
2017
34
Trichomoniasis and associated co-infections of the genital tract among pregnant women presenting at two hospitals in Ghana. ( 29237446 )
2017
35
Trichomoniasis - are we giving the deserved attention to the most common non-viral sexually transmitted disease worldwide? ( 28357378 )
2016
36
COMPARISON OF PERMANENT STAINING METHODS FOR THE LABORATORY DIAGNOSIS OF TRICHOMONIASIS. ( 26910452 )
2016
37
First report of an outbreak trichomoniasis in turkey in Sistan, Iran. ( 27065599 )
2016
38
Diagnosis of trichomoniasis in men by urine cytology. ( 27636204 )
2016
39
Prevalence of Trichomoniasis by PCR in Women Attending Health Screening in Korea. ( 27180577 )
2016
40
Trichomoniasis immunity and the involvement of the purinergic signaling. ( 27793265 )
2016
41
Prevalence of asymptomatic infections in sexually transmitted diseases attendees diagnosed with bacterial vaginosis, vaginal candidiasis, and trichomoniasis. ( 27890946 )
2016
42
Epidemiology of Trichomoniasis in South Korea and Increasing Trend in Incidence, Health Insurance Review and Assessment 2009-2014. ( 27936227 )
2016
43
Challenges and persistent questions in treatment of trichomoniasis. ( 27697044 )
2016
44
Rapid Antigen Testing for Trichomoniasis in an Emergency Department. ( 27207490 )
2016
45
Trichomoniasis in older individuals: a preliminary report from Iran. ( 27876991 )
2016
46
Can trichomoniasis cause pharyngitis? A case report. ( 28228954 )
2016
47
A molecular-beacon-based asymmetric PCR assay for easy visualization of amplicons in the diagnosis of trichomoniasis. ( 27318568 )
2016
48
Prevalence of Trichomoniasis among 18-48 Year-old Women in Northwest of Iran. ( 28127371 )
2016
49
A review of sexually transmitted bovine trichomoniasis and campylobacteriosis affecting cattle reproductive health. ( 26679515 )
2016
50
Comparative analysis of syndromic and PCR-based diagnostic assay reveals misdiagnosis/ overtreatment for trichomoniasis based on subjective judgment in symptomatic patients. ( 27146362 )
2016

Variations for Trichomoniasis

Expression for Trichomoniasis

Search GEO for disease gene expression data for Trichomoniasis.

Pathways for Trichomoniasis

GO Terms for Trichomoniasis

Cellular components related to Trichomoniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.1 ACOT7 ATAD2 IRF6 LAP3 TSPAN6 WASF3

Sources for Trichomoniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....